# A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

> **NCT01100606** · PHASE4 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 15 (actual)

## Conditions studied

- Cystic Fibrosis
- Exocrine Pancreatic Insufficiency

## Interventions

- **DRUG:** EUR-1008 (APT-1008)
- **DRUG:** EUR-1008 (APT-1008)

## Key facts

- **NCT ID:** NCT01100606
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01100606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01100606, "A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01100606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*